

ADMA BIOLOGICS, INC.  
Form 4  
December 04, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Grossman Adam S

(Last) (First) (Middle)

C/O ADMA BIOLOGICS, INC., 465  
STATE ROUTE 17

(Street)

RAMSEY, NJ 07446

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol

ADMA BIOLOGICS, INC. [ADMA]

3. Date of Earliest Transaction  
(Month/Day/Year)

12/02/2015

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

President & CEO

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, \$0.0001 par value per share	12/02/2015		P	500 A	\$ 9.1713 635,018 <sup>(1)</sup> <sub>(2)</sub>	I	Please see footnote <sup>(3)</sup>
Common Stock, \$0.0001 par value per share	12/02/2015		P	1,000 A	\$ 9.15 636,018 <sup>(1)</sup> <sub>(4)</sub>	I	Please see footnote <sup>(3)</sup>
Common Stock,	12/02/2015		P	750 A	\$ 9.1309 636,768 <sup>(1)</sup> <sub>(4)</sub>	D	

\$0.0001  
par value  
per share

(5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Grossman Adam S C/O ADMA BIOLOGICS, INC. 465 STATE ROUTE 17 RAMSEY, NJ 07446	X		President & CEO	

## Signatures

/s/ Adam Grossman  
12/04/2015

\*\*Signature of Reporting Person  
Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 580,957 of these shares are held by Hariden, LLC, an entity for which Adam Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.

## Edgar Filing: ADMA BIOLOGICS, INC. - Form 4

- (2) 48,300 of these shares are held by Areth LLC, an entity for which Adam Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.
- (3) These shares are being purchased by Areth LLC, an entity for which Adam Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.
- (4) 49,300 of these shares are held by Areth LLC, an entity for which Adam Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.

- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$9.1135 to \$9.1481 per share. The reporting person undertakes to provide to ADMA Biologics, Inc., any security holder of ADMA Biologics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased by it at each separate price on December 2, 2015.
- (5) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$9.1135 to \$9.1481 per share. The reporting person undertakes to provide to ADMA Biologics, Inc., any security holder of ADMA Biologics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased by it at each separate price on December 2, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.